These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24754260)

  • 41. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy.
    Hassoun Z; Deschênes M; Lafortune M; Dufresne MP; Perreault P; Lepanto L; Gianfelice D; Bui B; Pomier-Layrargues G
    Am J Gastroenterol; 2001 Apr; 96(4):1205-9. PubMed ID: 11316171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome.
    Kumamoto M; Toyonaga A; Inoue H; Miyakoda K; Morita Y; Emori K; Sakamoto Y; Oho K; Sata M
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1129-35. PubMed ID: 20594229
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement.
    Borentain P; Soussan J; Resseguier N; Botta-Fridlund D; Dufour JC; Gérolami R; Vidal V
    Diagn Interv Imaging; 2016 Jun; 97(6):643-50. PubMed ID: 26947721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of mortality in cirrhotic patients undergoing extrahepatic surgery: comparison of Child-Turcotte-Pugh and model for end-stage liver disease-based indices.
    Kim DH; Kim SH; Kim KS; Lee WJ; Kim NK; Noh SH; Kim CB
    ANZ J Surg; 2014 Nov; 84(11):832-6. PubMed ID: 23647879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Surgical approach to posthepatitic cirrhotic patient today].
    Meriggi F; Forni E
    G Chir; 1996; 17(6-7):370-8. PubMed ID: 9272983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts.
    Lucidi C; Ginanni Corradini S; Abraldes JG; Merli M; Tandon P; Ferri F; Parlati L; Lattanzi B; Poli E; Di Gregorio V; Farcomeni A; Riggio O
    Liver Transpl; 2016 Oct; 22(10):1333-42. PubMed ID: 27434824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score.
    Patel AV; Wade JB; Thacker LR; Sterling RK; Siddiqui MS; Stravitz RT; Sanyal AJ; Luketic V; Puri P; Fuchs M; Matherly S; White MB; Unser A; Heuman DM; Bajaj JS
    Clin Gastroenterol Hepatol; 2015 May; 13(5):987-91. PubMed ID: 25445772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New scoring systems for severity outcome of liver cirrhosis and hepatocellular carcinoma: current issues concerning the Child-Turcotte-Pugh score and the Model of End-Stage Liver Disease (MELD) score].
    Lee DH; Son JH; Kim TW
    Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):167-79. PubMed ID: 14515034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.
    Alvarez MA; Cirera I; Solà R; Bargalló A; Morillas RM; Planas R
    J Clin Gastroenterol; 2011; 45(10):906-11. PubMed ID: 21814145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transjugular intrahepatic portosystemic shunt in refractory hydrothorax - a contribution to an unexplored indication.
    Campos S; Gomes D; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):661-6. PubMed ID: 27002676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long term results of balloon-occluded retrograde transvenous obliteration for portosystemic shunt encephalopathy in patients with liver cirrhosis and portal hypertension.
    Inoue H; Emori K; Toyonaga A; Oho K; Kumamoto M; Haruta T; Mitsuyama K; Tsuruta O; Sata M
    Kurume Med J; 2014; 61(1-2):1-8. PubMed ID: 25420513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?
    Cholongitas E; Papatheodoridis GV; Vangeli M; Terreni N; Patch D; Burroughs AK
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1079-89. PubMed ID: 16305721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis.
    Radha Krishna Y; Saraswat VA; Das K; Himanshu G; Yachha SK; Aggarwal R; Choudhuri G
    Liver Int; 2009 Mar; 29(3):392-8. PubMed ID: 19267864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation.
    King A; Masterton G; Gunson B; Olliff S; Redhead D; Mangat K; Oniscu G; Hayes P; Tripathi D
    Liver Transpl; 2011 Jul; 17(7):771-8. PubMed ID: 21714062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
    Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
    Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in liver stiffness on real-time tissue elastography before and after occlusion of spontaneous portosystemic shunts.
    Kobayashi K; Hirota S; Kako Y; Yamamoto S; Takaki H; Yamakado K
    Diagn Interv Imaging; 2017 Apr; 98(4):321-326. PubMed ID: 27663139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model for End stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores: Ability to predict mortality and removal from liver transplantation waiting list due to poor medical conditions.
    Rahimi-Dehkordi N; Nourijelyani K; Nasiri-Tousi M; Ghodssi-Ghassemabadi R; Azmoudeh-Ardalan F; Nedjat S
    Arch Iran Med; 2014 Feb; 17(2):118-21. PubMed ID: 24527973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
    Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.
    Sharma P; Sharma BC
    Saudi J Gastroenterol; 2011; 17(2):138-41. PubMed ID: 21372353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.
    Riggio O; Ridola L; Angeloni S; Cerini F; Pasquale C; Attili AF; Fanelli F; Merli M; Salvatori FM
    J Hepatol; 2010 Aug; 53(2):267-72. PubMed ID: 20537753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.